Available evidence showing GCase reduced enzymatic activity in PD patients with and without GBA1 mutations has paved the way for the design and implementation of several approaches sharing the common ground of enhancing GCase function as putative disease-modifying therapies. This evidence concerns the gene GBA1 and Parkinson disease.